Showing results (41-50 of 75) with videos related to

Sort By:
Pageof 8
Cell Reports|December 21, 2017
BET Bromodomain Inhibition Synergizes with PARP Inhibitor in Epithelial Ovarian CancerSergey Karakashev, Hengrui Zhu, Yuhki Yokoyama, et al.
Cancer Immunology Research|April 30, 2014
Chemoimmunotherapy using pegylated liposomal Doxorubicin and interleukin-18 in recurrent ovarian cancer: a phase I dose-escalation studyFiona Simpkins, Aurea Flores, Christina Chu, et al.
O&G Open|September 26, 2025
Telehealth in Gynecologic Oncology Clinical Trials: Qualitative Study of Patient, Researcher, and Clinician PerspectivesLeslie Andriani, Linda M Saikali, Eion Plenn, et al.
BMC Health Services Research|February 14, 2025
Rideshare services for transportation assistance in gynecologic oncology: a quality improvement studyAnna Jo Smith, Sam Pancoe, Mary Pat Lynch, et al.
The Journal of Clinical Investigation|July 26, 2016
RING domain-deficient BRCA1 promotes PARP inhibitor and platinum resistanceYifan Wang, John J Krais, Andrea J Bernhardy, et al.
Supportive Care in Cancer : Official Journal of the Multinational Association of Supportive Care in Cancer|March 31, 2016
Race-based disparities in loss of functional independence after hysterectomy for uterine cancerLorraine T Dean, Xiaochen Zhang, Nawar Latif, et al.
Molecular Therapy : the Journal of the American Society of Gene Therapy|December 25, 2019
CAR T Cells Targeting MISIIR for the Treatment of Ovarian Cancer and Other Gynecologic MalignanciesAlba Rodriguez-Garcia, Prannda Sharma, Mathilde Poussin, et al.
Gynecologic Oncology|December 11, 2019
An autologous humanized patient-derived-xenograft platform to evaluate immunotherapy in ovarian cancerSarah B Gitto, Hyoung Kim, Stavros Rafail, et al.
International Journal of Gynecological Cancer : Official Journal of the International Gynecological Cancer Society|December 11, 2012
Patterns of recurrence in stage I endometrioid endometrial adenocarcinoma with lymphovascular space invasionFiona Simpkins, Andrea Papadia, Charles Kunos, et al.
Gynecologic Oncology|July 8, 2022
Olaparib treatment for platinum-sensitive relapsed ovarian cancer by BRCA mutation and homologous recombination deficiency status: Phase II LIGHT study primary analysisKaren Cadoo, Fiona Simpkins, Cara Mathews, et al.
Pageof 8